Arena Pharmaceuticals Inc (NASDAQ:ARNA) Shorted Shares Strengthened By 2.11%

May 16, 2018 - By Eula Gilbert

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Corporate Logo

It was registered an increase on Arena Pharmaceuticals Inc (NASDAQ:ARNA)’s shorted shares with 2.11%. It was issued in May by FINRA the 3.79 million shorted shares on ARNA. The 3.71 million previous shares are up with 2.11%. With Average volume 926,000, ARNA’s former position will take 4 days to restore. Float short on Arena Pharmaceuticals Inc is 9.68%.

Ticker’s shares touched $46.56 during the last trading session after 0.28% change.Arena Pharmaceuticals, Inc. has volume of 544,285 shares. Since May 16, 2017 ARNA has risen 169.40% and is uptrending. The stock outperformed the S&P 500 by 157.85%.

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for various therapeutic areas in the United States and Switzerland.The firm is valued at $2.28 billion. The companyÂ’s proprietary investigational clinical programs include etrasimod , which is in Phase IIb evaluation for ulcerative colitis, as well as is in Phase IIa evaluation for dermatologic extraintestinal manifestations in inflammatory bowel disease, pyoderma gangrenosum, and primary biliary cholangitis; ralinepag that is in Phase IIb evaluation to treat pulmonary arterial hypertension; and APD371, which is in Phase IIa evaluation for the treatment of pain associated with Crohn's disease.Last it reported negative earnings. It has collaboration agreements with Eisai Inc.; Eisai Co., Ltd.; Axovant Sciences Ltd.; and Boehringer Ingelheim International GmbH.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Ratings Coverage

A total of 7 analysts rate Arena Pharmaceuticals (NASDAQ:ARNA) as follows: 6 “Buy”, 1 “Hold” and 0 “Sell”. Тherefore 86% are bullish. (NASDAQ:ARNA) has 14 ratings reports on May 16, 2018 according to StockzIntelligence. On Tuesday, March 20 the stock of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has “Buy” rating given by Wells Fargo. On Wednesday, April 18 the firm has “Buy” rating by Cantor Fitzgerald given. The company rating was upgraded by Wells Fargo on Wednesday, January 3. On Wednesday, May 9 the stock has “Buy” rating by Cantor Fitzgerald. The stock rating was upgraded by Needham to “Buy” on Tuesday, March 20. In Thursday, January 4 report Cantor Fitzgerald maintained it with “Buy” rating and $45.0 target. On Wednesday, March 14 the company was maintained by Cantor Fitzgerald. The company rating was maintained by Cantor Fitzgerald on Monday, February 26. On Wednesday, January 17 the stock of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has “Buy” rating given by Leerink Swann. On Tuesday, February 27 the rating was maintained by Citigroup with “Buy”.

For more Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) news posted recently go to: Streetinsider.com, Streetinsider.com, Globenewswire.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “Omega’s 13F Shows Increase in Ocwen (OCN), Synchrony (SYF), United (UAL), Exits Zynga (ZNGA) (More…)” posted on May 15, 2018, “Arena Pharma (ARNA), Outpost Medicine Enter into Licensing Agreement for Undisclosed Novel Compound” on May 01, 2018, “Report: Developing Opportunities within Haemonetics, Arena Pharmaceuticals, Xperi, MoneyGram International, Boot …” with a publish date: May 15, 2018, “My 2 Cents On The Ozanimod Saga” and the last “Arena Pharmaceuticals’ (ARNA) CEO Amit Munshi on Q1 2018 Results – Earnings Call Transcript” with publication date: May 15, 2018.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: